Pilot Study of Open Label Homocysteine Management Therapy in Levodopa-treated Parkinson's Disease

Recruiting now · Not applicable

Conditions studied: Parkinson&Amp;#39;s Disease

In brief

This is a research study investigating elevated homocysteine in the blood of patients with Parkinson's disease who are currently receiving treatment with levodopa. We are evaluating if elevated homocysteine can be corrected using open label B vitamin therapy, as well as the impact of homocysteine levels on cognitive function.

Key facts

Study ID

NCT06772220

Run by

Oregon Health and Science University

People needed

150

Starts

2024-03-05

Expected to finish

2025-12-31

Last updated by the study team

2025-01-13

Who can join

Age: 40 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of probable Parkinson's Disease according to Movement Disorders Society criteria.
• Currently treated with levodopa at a minimum dose of 300 mg/day
• Montreal Cognitive Assessment (MOCA) ≥15
• Demonstrated capacity to provide informed consent.
• 40-90 years of age
• Estimated glomerular filtration rate ≥60
• Absence of uncontrolled hypertension in medical history
• Absence of insulin use

Where it is running

• Oregon Health & Science University (OHSU) — Portland, Oregon, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.